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Abstract White matter pathologies are critically involved in the etiology of vascular cognitive
impairment–dementia (VCID), Alzheimer’s disease
(AD), and Alzheimer’s disease and related diseases
(ADRD), and therefore need to be considered a treatable target ( Roseborough A, Hachinski V, Whitehead
S. White matter degeneration - a treatable target?
Roseborough et al. JAMA Neurol [Internet]. 2020
Apr 27;77(7):793–4, [1] . To help address this often-

missed area of research, several workshops have
been sponsored by the Leo and Anne Albert Charitable Trust since 2015, resulting in the incorporation
of “The Albert Research Institute for White Matter
and Cognition” in 2020. The first annual “Institute”
meeting was held virtually on March 3–4, 2021. The
Institute provides a forum and workspace for communication and support of the advancement of white
matter science and research to better understand the
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evolution and prevention of dementia. It serves as a
platform for young investigator development, to introduce new data and debate biology mechanisms and
new ideas, and to encourage and support new research
collaborations and directions to clarify how white
matter changes, with other genetic and health risk factors, contribute to cognitive impairment. Similar to
previous Albert Trust–sponsored workshops (Barone
et al. in J Transl Med 14:1–14, [2]; Sorond et al. in
GeroScience 42:81–96, [3]), established expert investigators were identified and invited to present. Opportunities to attend and present were also extended by
invitation to talented research fellows and younger
scientists. Also, updates on institute-funded research
collaborations were provided and discussed. The
summary that follows is a synopsis of topics and discussion covered in the workshop.
Keywords White matter · Cognition ·
Neurodegenerative disease/injury · AD · VCID
Introduction
According to the World Health Organization, in the
year 2050 one in five of the world’s population will
be over the age of 60, with approximately 115 million individuals affected by dementia [4]. In addition
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to this number, nearly 20% of elderly individuals will
be predicted to suffer from mild cognitive impairment, which occurs years prior to dementia [5]. To
date, most therapies aim to protect/preserve at-risk
neurons, but very few target the brain white matter,
which makes up half of the brain and can be a critical site of prodromal disease. While neuronal loss
within the gray matter is a widely studied feature of
aging, the parallel (and potentially preceding) loss of
white matter has garnered less attention. White matter is well recognized to be particularly vulnerable to
cerebrovascular injury [6, 7]. Accordingly, white matter pathology is commonly seen in VCID [8], most
often presenting with cognitive slowing and executive dysfunction [9, 10]. This vulnerability has been
attributed, in part, to the nature of cerebral vascular
anatomy [11–15]. However, the active and contributing role of glial cells in white matter vascular injury
has been demonstrated by the inhibition and modulation of these cells in recent experimental models
[16–22]. Additionally, impairments in white matter
structure and function are a core feature of aging, are
one of the earliest pathological features of Alzheimer
disease (AD), and are a significant risk factor for cerebrovascular disease [1, 23].
White matter changes are detectable on neuroimaging, beginning in midlife with a prevalence as
high as 50% by the individuals in their 40 s [24].
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Traditionally, white matter changes are detected
using magnetic resonance imaging (MRI) using
T2 weighted fluid attenuated inversion recovery
(FLAIR), appearing as white matter hyperintensities
(WMH). The etiology and development of WMH are
heterogeneous, but usually involve a loss of myelin
and axon density, the primary end-stage pathological correlates of WMH [25]. Within both gray and
white matter, glial cells present critical targets for
therapeutic intervention and neuroprotection [26–28].
This pertains to VCID as well as Alzheimer disease
(AD), as the roles of both cerebrovascular and executive dysfunction are now increasingly appreciated
as common factors of AD [8, 29–33]. Additionally,
investigation of the neurovascular unit (NVU) in neurodegenerative disease has identified an important
intersection between cerebrovascular and glial pathology [34].
Synopsis of 3–4 March 2021 Albert Research
Institute for White Matter and Cognition
workshop
The recent workshop scientific program was organized into four topics: (i) cerebrovascular disease:
models, markers, and mediator mechanisms (Faraco,
Zuloaga, Carmichael, Tse, Shih); (ii) epidemiology, aging, and neurovascular dysregulation (Gufstafson, Ungvari, Elahi, Csiszar); (iii) white matter,
brain imaging, and biomarkers (Hachinski, Wilcock,
Gould, Edwards); and (iv) white matter, brain protection, and mechanisms (Burns, Bruno, Seshadri). Due
to the ongoing COVID-19 pandemic at this time, the
meeting was held virtually over 2 days via Zoom, and
individual synopses of the talks are provided below.
Gut flora, immune‑mediated neurovascular
dysfunction and tau accumulation
Guiseppe Faraco
The intestinal flora is essential for the development of
gut-associated lymphoid tissue and for maintaining
the homeostasis of the immune system. IL-17-producing T-helper lymphocytes (Th17 cells) are particularly abundant in GALT and play a major role in
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the cognitive dysfunction associated with high-salt
diet in mice [35, 36]. This harmful effect depends on
circulating IL17 acting on cerebral endothelial cells to
induce a deficit in endothelial nitric oxide, leading to
tau phosphorylation and aggregation. These observations raise the possibility that gut dysbiosis, resulting
in increased Th17 differentiation, may lead to cognitive impairment through tau. To test this hypothesis,
we co-housed C57BL6 mice from Jackson Laboratory
(Jax) with C57BL6 mice from Taconic Biosciences,
the microbiota of which is notable for the presence
of segmented filamentous bacteria, potent inducers
of Th17 cells. Owing to their coprophagic behavior,
sharing the same cage resulted in colonization of Jax
mice by SFB and, in turn, increased IL17 mRNA
levels in the distal small intestine. Circulating levels
of IL-17 were also increased in Jax mice after cohousing. Neurovascular coupling and endotheliumdependent vasodilation were impaired, and brain tau
phosphorylation was increased in Jax mice. Furthermore, Jax mice showed deficits in spatial memory
assessed by the Barnes maze. Although additional
studies are needed to further elucidate the underlying
mechanisms, these studies unveil a previously unrecognized link between changes in gut microbiota and
tau phosphorylation and may provide new insights in
the pathobiology of AD and other tauopathies with
potential therapeutic relevance.
Sex differences in metabolic and hormonal
contributions to VCID
Kristen L. Zuloaga
Mid-life metabolic disease causes cerebrovascular
dysfunction and is a risk factor for VCID. The effect
of metabolic disease on VCID risk is even greater
for women compared to men. In line with this clinical data, using mouse models of metabolic disease
(chronic high fat diet) and VCID (chronic cerebral
hypoperfusion), we have found that high-fat diet
causes greater metabolic impairment and a wider
array of cognitive deficits in middle-aged females
compared to males [37]. We have found that metabolic disease severity is more strongly associated
with white matter damage, astrogliosis [38], and
reduced neurogenesis [39] in females compared to
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males. The increased susceptibility in females may
be related to endocrine aging. Women are unique in
that they go through menopause, with loss of estradiol. Estradiol has protective effects on white matter,
gray matter, the vasculature, and metabolism. Menopause accelerates mid-life risk factors for dementia,
by increasing risk for cardiovascular and metabolic
diseases. Despite the fact that nearly all women with
VCID are post-menopausal, the influence of menopause on VCID and underlying pathology is a critical gap in knowledge. Using an accelerated ovarian
failure model of menopause in mice, we have recently
found that longer time in menopause is associated
with increased memory impairment in a mouse model
of VCID. Our next steps will be to determine if the
underlying pathologies are affected. We anticipate
these studies will provide mechanistic insight that
will facilitate future interventions to decrease the burden of VCID in the high-risk population of post-menopausal women with metabolic disease.
Neural repair after white matter stroke
S. Thomas Carmichael
White matter stroke progresses into adjacent white
matter over time, and white matter lesions accumulate
to produce vascular dementia [40, 41]. In inflammatory diseases of white matter, such as multiple sclerosis, there is a process of white matter repair early
in the course of disease, produced through oligodendrocyte progenitor cell (OPC) responses [42]. OPCs
sense the lesion, and proliferate and differentiate into
mature oligodendrocytes. Such a process does not
happen in white matter stroke, despite an initial similar size and location of ischemic white matter lesions
as compared to multiple sclerosis plaques [43, 44].
In a mouse model of white matter stroke/vascular
dementia, we have identified the molecular responses
of OPCs as a function of age (young vs aged adult),
time after stroke and with stroke in comparison to
other types of white matter lesions. These data indicate a specific deficit in subtypes of OPCs with normal aging, impairment in OPC differentiation with
age and an inflammatory OPC that occurs in stroke.
In a separate series of questions, behavioral action
and neural activity promote white matter structure
and function in a variety of contexts. Can specific
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types of neurorehabilitation promote white matter
repair in white matter stroke/vascular dementia? If so,
is there a specific molecular system that is induced
by neurorehabilitation that might serve as a therapeutic target? We will show evidence for the effect of
neuro-rehabilitative therapies on white matter repair
in mouse white matter stroke.
TRIM47 in white matter hyperintensity:
from the population to the cell
K.H. Tse
WHM represent a radiopathology highly associated
with cognitive declines in aging, vascular dementia, and Alzheimer’s disease. Different genome-wide
association studies (GWAS) commonly identified single nucleotide polymorphisms (SNPs) at the 17q25
locus spanning the genes of Tripartite motif (TRIM)
family, a group of E3 ubiquitin ligase proteins, associated with WMH. In particular, multiple SNPs were
detected in TRIM47 [45, 46]. We wished to test the
hypothesis that TRIM47 is a critical protein that contributes to the pathogenesis of WMH. However, as
the expression and function of TRIM47 in the brain
remain obscure, we undertook to establish the basic
characteristics and roles of TRIM47 in the pathogenesis of WMH. In the exploration of RNA-seq
datasets of human tissues and mouse brain, we first
confirmed that TRIM47 is enriched in the cerebral
cortex, where it is highly expressed by brain endothelial cells. Our immunohistochemistry experiments
validated that TRIM47 proteins are specifically localized in endothelial cells of postmortem human brain
tissues. In an acute mouse model of WMH (BCAS;
bilateral common carotid arteries stenosis), minimal
changes in BCAS were found, but a significant upregulation of Trim47 was detected in hAPOE4 mice
(humanized APOE4) correlated with a heretofore
unreported propensity toward periventricular WMH.
We have also investigated the change of TRIM47
on a murine brain-derived endothelial cell model
under an ischemic-like conditions. While TRIM47
was unaffected by oxidative stress, it was upregulated by hypoglycemic conditions at the mRNA level.
Intriguingly, genetic silencing of Trim47 significantly
increased the expression of LC3 punta and the formation of vacuoles in endothelial cells and exaggerated
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their responses to hypoglycemia, where confocal
microscopy revealed a proximity between LC3 and
TRIM47. Structural analysis revealed the existence of a LC3-interacting motif (LIR) in TRIM47,
where their putative interaction with LC3 was found
in a protein–protein interaction model in silico and
observed by super-resolution microscopy. Together,
the present study characterized the expression pattern
and the potential function of TRIM47 in mouse and
human brain. Importantly, our preliminary data connects TRIM47 to autophagy, a key cellular mechanism underlying cerebrovascular remodeling in the
aging brain. These findings will help us to understand
the cell biology underlying WMH pathogenesis and
warrant further investigation.
Deep multi‑photon imaging of capillary drainage
at gray‑white matter interface in mice
Andy Y. Shih
Our understanding of brain microcirculation mostly
comes from studying arteriolar perfusion. However,
blood drainage through venules is equally important
in regulating cerebral blood flow. Properties of cerebral venules can change dramatically during cerebrovascular disease and aging. Understanding the
regulation of blood drainage in and near white matter tracts is critical in elucidating the basis of white
matter degeneration in early stages of ADRD. We
studied principal cortical venules (PCVs), massive
ascending venules extending from the brain surface
to the deepest layers of cortex and underlying white
matter. Deep in vivo two-photon imaging was used
to perform structural and functional characterization
of PCV vascular networks in adult (5–7 months) and
aged mice (22–24 months). The study reveals cortical
layer specific changes in the structural and hemodynamic properties of PCV capillary networks. Namely,
capillaries draining cortical layer 6 and the superficial white matter exhibit reduced diameter, blood
cell flux, and velocity, as well as increased lengths
and tortuosity with advanced age. We also show that
in vivo three-photon imaging is applicable for interrogation of microvascular networks in deeper aspects
of the white matter. This novel imaging study of
healthy adult and aged mice provides an experimental foundation for studies of venular dysfunction as a
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mechanism of impaired cerebral blood flow and white
matter degeneration in ADRD.
Epidemiology informs interventions for VCID
Deborah R. Gustafson
Observational epidemiology studies show differential
associations between vascular risk factors and both
clinical and neuropathological brain aging outcomes.
Associations between individual vascular risk factors
and individual symptoms–neuropathology of VCID,
ADRD, and cerebrovascular small vessel disease
(CSVD) across diverse, global populations facilitate
identification of disease mechanisms, susceptible
populations, and intervention targets. Greater attention to “fit for purpose and fit for community” results
in better planning of interventions for VCID, ADRD,
and CSVD [47]. Peripheral measures of adiposity as
the vascular risk factor and exposure in relation to
brain health are provided using two examples. The
first example involves CSVD brain imaging outcomes
in the RUN DMC study of 503 adults with CSVD,
age ≥ 50 years. RUN DMC reported differences in
cross-sectional versus longitudinal adiposity associations, in association with volumetric and vascular
brain hallmarks of VCID and ADRD. Differences by
anthropometric versus metabolic adiposity measures,
sex, and survivorship were observed [48]. The second
example is unpublished data from the Women’s Interagency HIV Study. During middle age, from average
age 38–48 years, a single timepoint versus 10-year
change in adiposity measures differed in association
with neuropsychological performance at 10 years,
particularly in HIV-infected women. Translating the
observational epidemiology to interventions must
consider the following: (1) changing vascular phenotypes over the life course; (2) characteristics of populations at risk; (3) multi-morbidities; (4) duration of
exposure(s), such as medications; (5) birth cohort;
and (6) genetic susceptibility. Embracing the details
will better identify optimal VCID and CSVD intervention strategies [47, 49].
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Role of NAD + deficiency in neurovascular
and cognitive aging

New tools for studies of neurovascular aging
and dysfunction in humans

Zoltan Ungvari

Fanny Elahi

Adjustment of cerebral blood flow (CBF) to neuronal activity via neurovascular coupling (NVC) has
an essential role in maintenance of healthy cognitive function [50]. Aging increased oxidative stress
and cerebral microvascular endothelial dysfunction
impairs NVC, contributing to cognitive decline [51].
There is increasing evidence showing that a decrease
in NAD+ availability with age plays a critical role
in age-related cerebral microvascular impairment
and that restoring N
 AD+ concentration exerts beneficial effects on the neurovascular unit [52]. When
24-month-old mice were treated with nicotinamide
mononucleotide (NMN), a key N
 AD+ intermediate,
for 2 weeks, endothelial NO-mediated vasodilation
and NVC responses (assessed by measuring CBF
responses evoked by contralateral whisker stimulation) were rescued, which was associated with significantly improved cognitive performance. Transcriptome analysis of preparations enriched for cells of the
neurovascular unit was performed by RNA-seq. We
identified 590 genes differentially expressed in the
aged neurovascular unit, 204 of which are restored
toward youthful expression levels by NMN treatment.
The transcriptional footprint of NMN treatment indicates that increased NAD + levels promote SIRT1
activation in the neurovascular unit, as demonstrated
by analysis of upstream regulators of differentially
expressed genes as well as analysis of the expression
of known SIRT1-dependent genes. Pathway analysis
predicts that neurovascular protective effects of NMN
are mediated by the induction of genes involved in
mitochondrial rejuvenation, anti-inflammatory and
anti-apoptotic pathways. These findings are paralleled
by the sirtuin-dependent protective effects of NMN
on mitochondrial production of reactive oxygen species and mitochondrial bioenergetics in cultured cerebral microvascular endothelial cells derived from
aged animals. Thus, a decrease in N
 AD+ availability
contributes to age-related microvascular dysfunction,
exacerbating cognitive decline. The cerebral microvascular protective effects of NMN highlight the preventive and therapeutic potential of N
 AD+ intermediates as effective interventions in patients at risk for
VCID.

Although vascular risk and disease are known
clinical contributors to cognitive impairment and
dementia, the cellular and molecular underpinnings of VCID remain more obscure. In our model
of white matter disease and VCID pathogenesis, we
posit that vascular risk factors and systemic innate
immune activation are associated with endothelial
injury and inflammation, with phenotypic change
in endothelial cells contributing to impairment of
the blood–brain barrier (BBB), followed by CNS
immune activation and neurodegeneration. To
begin testing this multi-component disease model,
we have worked on developing an approach that
combines specificity for endothelial cells with sensitivity for molecules within pathways of interest.
We use sensitive quantitative methods to analyze
molecular cargo from plasma endothelial-derived
extracellular vesicles (EDE) as a “liquid biopsy”
approach of endothelial cells. Using this approach,
we have thus far shown (1) that plasma EDE capture
molecular cargo that are relevant to brain endothelial cells, PMID: 30483114 and PMID: 32157747
(2) that EDE molecular cargo in aging adults with
vascular risk or white matter disease have higher
levels of complement factors, PMID: 34376699 and
(3) that EDE-complement levels are associated with
clinically meaningful outcomes in VCID, such as
cognitive processing speed and executive function
PMID: 34376699. This approach could provide the
much needed cellular specificity in molecular measurements from human biospecimen to allow better
translation between mechanistic studies in reductionist systems and molecular dysregulations in
complex systems such as human aging and disease.
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Potential role of neurovascular senescence
in cognitive decline
Anna Csiszar
Age-related phenotypic changes of cerebral microvascular endothelial cells lead to dysregulation of

GeroScience (2022) 44:25–37

cerebral blood flow and blood–brain barrier disruption, promoting the pathogenesis of VCID [51, 53]. In
recent years, endothelial cell senescence has emerged
as a potential mechanism contributing to microvascular pathologies [54, 55], opening the avenue to the
therapeutic exploitation of senolytic drugs in preclinical studies [56]. To detect senescent endothelial cells
in the aging mouse brain, we analyzed 4233 cells
in fractions enriched for microvascular endothelial
cells and other cells associated with the neurovascular unit obtained from young (3-month-old) and
aged (28-month-old) C57BL/6 mice. We defined 13
transcriptomic cell types by deep, single-cell RNA
sequencing. We matched transcriptomic signatures of
cellular senescence to endothelial cells identified on
the basis of their gene expression profile. Our study
demonstrates that with advanced aging there is an
increased ratio of senescent endothelial cells (~ 10%)
in the mouse cerebral microcirculation. Spatial transcriptomics confirmed the increased presence of
senescent cells in the white matter as well as in the
hippocampus and cortex of the aged mouse brain. To
evaluate the efficiency of a translationally relevant
senolytic regimen, we treated aged mice with the
BCL-2/BCL-xL inhibitor senolytic drug ABT263/
Navitoclax. We found that Navitoclax improves functional hyperemia in aged mice that associates with
improved cognitive performance. Our results open
the avenue to the therapeutic exploitation of senolytic
drugs in multiple age-related cerebrovascular pathologies in preclinical studies.
Leukoaraiosis: 3 decades later
Vladimir Hachinski
The advent of brain imaging in the 1980s began
revealing white matter changes that were promptly
equated with “Binswanger disease.” However,
Binswanger disease is neither Binswanger’s nor a disease. We suggested that the white matter changes had
diverse causes but a common denominator: decreased
density. Thus, we coined the term “leukoaraiosis”
(LA) based on ancient Greek: Leuko meaning white
and araiosis, less dense. Although it remains true that
LA has many causes, the concept of the ambibaric
brain helps explain the pathogenesis and symptomology of LA associated with vascular disease. The
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brainstem, basal ganglia, and thalamus are supplied
by short end arteries (primitive brain). Having to step
down arterial to capillary pressure makes these arteries a high-pressure system vulnerable to hypertension. By contrast, the arteries that supply the hemispheres (Homo sapiens brain) have long distances to
step down the pressure before they supply the brain,
making them a low-pressure system. Thus, the brain
circulation contains two (ambi) complementary pressure (baric) systems. Damage to the blood vessels of
the primitive brain can result in damage to the frontal
systems resulting in executive dysfunction, gait slowing, and apathy. Hypertension is a highly prevalent
and treatable cause of small vessel disease and the
resulting symptomology. LA can be an early warning system for cognitive impairment and stroke and
a growingly attractive therapeutic and prevention
target.
Placental growth factor as a mediator of small
vessel disease
Donna M. Wilcock
VCID is an important and understudied cause of cognitive impairment, often co-morbid with Alzheimer’s
disease and other neurodegenerative conditions. Diffuse white matter disease (DWD) is apparent on MRI,
appearing as WMH. It has long been considered to be
a consequence of cerebrovascular pathology; more
specifically small vessel disease resulting from hypertension and microinfarcts. Much like the pathologic
angiogenesis that occurs in retinopathies, pathologic
angiogenesis in the brain results in blood–brain barrier leakage and, counterintuitively, tissue ischemia.
We have examined plasma and CSF angiogenic
mediators in a cohort of 120 research participants
who also have a range of cognitive impairments and
severity of WMH changes on MRI. We found several
members of the vascular endothelial growth factor
(VEGF) family, in particular placental growth factor
(PlGF), which is significantly associated with WMH
growth and cognitive measures, especially executive
function measures. We have examined post-mortem
autopsy tissue to determine PlGF expression in the
human brain, and we found strong immunostaining in
the white matter of individuals with small vessel disease, primarily perivascular labeling. Such staining
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was significantly less in the brains of age-matched,
pathology-free individuals. We also performed exosome studies in plasma and found that the primary
source of PlGF in the plasma is astrocytic, and also
there is some PlGF in endothelial exosomes.
Roles for Col4a1 and Col4a2 in cerebral small
vessel disease
Douglas B. Gould
VCID describes a spectrum of cognitive changes with
primary vascular origins and is a significant global
health problem. However, a lack of understanding of
the pathogenic mechanisms is a barrier to developing
specific interventional strategies. CSVD is a leading
cause of stroke and VCID and includes WMH, enlarged
perivascular spaces (PVS), lacunar infarcts, cerebral
microbleeds, and intracerebral hemorrhages. Familial
and sporadic forms of CSVD share clinical and radiological features suggesting that monogenic forms of
CSVD may represent experimentally tractable models
with which to identify pathogenic processes underlying common and chronic disease subtypes. Type IV
collagen alpha 1 (COL4A1) and alpha 2 (COL4A2)
are extracellular matrix proteins that form heterotrimers deposited into basement membranes of nearly all
tissues. Semi-dominant mutations of COL4A1 and
COL4A2 cause a congenital multisystem disorder that
includes highly penetrant cerebrovascular disease and
commonly manifests as porencephaly, stroke, WMH,
subcortical MB, enlarged PVS, and lacunar infarctions
REFS - PMID: 26610912 and 27794444. Importantly,
COL4A2 is the most consistently associated with manifestations of CSVD and VCID in genome-wide association studies. Using Col4a1 mutant mouse models, we
observe both mural cell defects during developmental
angiogenesis and arterial smooth muscle cell degeneration in aged mice suggesting that impaired mural
cell function is an important aspect of the pathology.
Using a therapeutic intervention that corrects COL4A1
misfolding and secretion prevents pathology in mouse
models and may represent a therapeutic avenue.
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Does the heart matter for your white matter?
Novel cardiac markers of dementia risk
Jodi D. Edwards
Atrial fibrillation (AF) is the most common cardiac
arrhythmia [57] and a major cardiac cause of stroke
[58]. AF is also associated with an estimated 33%
increased risk of dementia independent of stroke [59].
However, since AF is frequently intermittent or clinically silent, existing prediction tools are limited for
identifying those at high risk of AF-related stroke
and dementia. Left atrial cardiopathy is the process of
structural and electrical remodeling preceding clinically manifest AF. Markers of left atrial cardiopathy
including increased P-wave terminal in lead V
 1, left
atrial enlargement, and excessive atrial ectopy increase
the risk of AF and have recently been identified as a
direct risk factor for stroke in the absence of AF [60].
Further, preliminary studies have shown that left atrial
cardiomyopathy may also increase the risk of cognitive
decline [61], suggesting that detection of atrial cardiopathy might represent an important opportunity to
improve the estimation of dementia risk in aging adults.
This workshop reviews evidence for atrial cardiomyopathy as a novel cardiac marker of stroke and dementia
risk and highlights ongoing studies in the Brain Heart
Nexus Research Program examining these and other
novel markers of dementia risk.
Exercise, brain health, and Alzheimer’s disease
Jeff Burns
Physical exercise may represent an important strategy
for preventing, delaying the onset, or slowing the progression of AD in older adults. Our clinical and translational research suggest exercise-relevant metabolic
abnormalities are present in the earliest clinical stages
of AD [62]. We have reported that individuals in the
earliest clinical stages of AD have alterations in muscle mass [63], bone density [64, 65], and peak oxygen
consumption (VO2peak) [66–68] while these alterations in metabolic measures correlate with the degree
of brain atrophy or cognitive decline. Our randomized
controlled trial data suggests aerobic exercise may
counteract some of these changes and influence brain
structure and function in older adults both with [69]
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and without AD [70]. In early AD, exercise-related
increases in V02 peak are associated with improved
memory performance and reduced hippocampal
atrophy over 6 months [69]. In older adults without
cognitive impairment, a dose–response relationship
likely exists between aerobic exercise and cognition,
beginning with low doses (75 min/week) and with
apparent increased benefits at higher doses in those
who adhered to the exercise protocol [70]. The benefits of exercise for brain health do not appear to be
related to mitigation of cerebral amyloid. In a 1-year
RCT of exercise vs stretching (n = 110), we found
no exercise-related effect on cerebral amyloid levels
(amyloid positron emission tomography) in healthy
unimpaired adults with subclinical or elevated cerebral amyloid [71]. Our data suggests a cardiorespiratory fitness response appears to be important for brain
benefits and thus maximizing an individual’s cardiorespiratory fitness may be an important therapeutic
target for achieving cognitive benefits.
Remote ischemic conditioning for white matter
health
Askiel Bruno
Intermittent compression of the extremities with a
blood pressure cuff inflated above the systolic blood
pressure has been reported to exert remote vascular
benefits, such as protection against subsequent heart
and brain ischemia [72]. This intervention has been
labeled remote ischemic conditioning (RIC) and has
been usually applied daily to both arms with four
cycles of 5 min alternating compression and decompression. Impressive vascular benefits from RIC have
been reported in animal studies [73]. Many human
RIC studies also show promising results [74, 75]. The
mechanism by which RIC leads to vascular benefits
is not yet completely understood and includes neural
spinal pathways and various humoral factors leading
to improved blood flow to multiple tissues. The associated humoral factors include nitric oxide, various
ant-inflammatory, and various neuroprotective factors. RIC is a safe and inexpensive intervention that
appears promising to improve the cerebral circulation
and consequently possibly protect against age-related
cerebral white matter damage. RIC warrants further
scientific clinical investigation.
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New information learned and future small Albert
White Matter and Cognition workshops
This year’s Albert Research Institute workshop provided the exchange of new white matter and cognition
knowledge on several fronts that include but not limited to the following:
• Changes in gut microbiota can be involved in
brain tau phosphorylation and dementia.
• Female sex and adiposity can increase cognitive
loss. Aging increases oxidative stress and brain
microvascular endothelial dysfunction to impair
NVC and contribute to cognitive decline. NVC
has an essential role in maintenance of healthy
cognitive function.
• Advanced age tortuosity reduces perfusion-flow
velocity of cortical capillaries and white matter.
• E3 ubiquitin ligase TRIM47 is involved in agerelated PVC cerebrovascular remodeling that contributes to the pathogenesis of WMH and injury.
• OPC loss/injury is critical to white matter injury
and most importantly to its repair.
• Associations between vascular risk factors across
diverse populations can facilitate understanding
of disease mechanisms in susceptible populations
and point us to potential intervention targets.
• NAD+ intermediates have potential as effective
interventions in patients at risk for VCID.
• High complement factor levels of plasma EDE in
aging, vascular risk, or white matter disease are
associated with deficits in cognitive processing
speed and executive function.
• Spatial transcriptomic work confirmed increased
white matter and cortex-hippocampus senescent
cells in aged mice. The BCL-2/BCL-xL inhibitor
Navitoclax improves functional hyperemia and
cognitive performance in aged mice.
• Damage to the blood vessels of the primitive
brain can result in damage to the frontal systems
resulting in executive dysfunction, gait slowing,
and apathy.
• Hypertension is a highly prevalent and treatable
cause of small vessel disease and VCID. LA can
be an early warning system for cognitive impairment and stroke.
• Increased PlGF perivascular immunostaining
occurs in the white matter CSVD. Plasma exo-
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some work indicated astrocytes and endothelial
cells were the PIGF source.
Col4a1 mutant mice indicate that impaired mural
cell function is an important aspect of the VCID
pathology. Therapeutic correction of COL4A1
misfolding and secretion prevents pathology.
Atrial cardiomyopathy is a novel cardiac marker
of stroke and dementia risk.
Cardiorespiratory fitness can be therapeutic and
provide cognitive benefits in AD.
RIC is a safe and inexpensive intervention to
improve the cerebral circulation and protect
against age-related cerebral white matter damage.

One recurrent meeting theme was the importance
of age-related endothelial cell phenotypic changes
that lead to dysregulation of cerebral blood flow
and BBB disruption that promotes the pathogenesis
of VCID. Vascular risk factors and systemic innate
immune activation are associated with endothelial
injury and inflammation that contributes to impaired
BBB and NVC that is followed by CNS immune
activation and neurodegeneration. The participants
identified a need for discussions of the VCID and
white matter animal models currently used and
those that need to be developed. Since this first virtual annual workshop allowed the virtual attendance of participant-presenter lab members and junior scientists/fellows, although the highly effective
small workshop model perpetuated in the Leo and
Anne Albert Trust–sponsored scientific meetings,
the pandemic has opened new virtual connections to
extend communications and interactions/growth in
future mixed live-virtual future workshop settings.
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